MediPharm Labs Corp. (MEDIF)
| Market Cap | 24.27M |
| Revenue (ttm) | 29.91M |
| Net Income (ttm) | -5.20M |
| Shares Out | n/a |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 21,291 |
| Average Volume | 212,243 |
| Open | 0.0595 |
| Previous Close | 0.0573 |
| Day's Range | 0.0543 - 0.0596 |
| 52-Week Range | 0.0374 - 0.0850 |
| Beta | 0.30 |
| RSI | 48.98 |
| Earnings Date | May 15, 2025 |
About MediPharm Labs
MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, develops, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll canna... [Read more]
Full Company ProfileFinancial Performance
In 2024, MediPharm Labs's revenue was 41.96 million, an increase of 26.92% compared to the previous year's 33.06 million. Losses were -10.69 million, -18.26% less than in 2023.
Financial numbers in CAD Financial StatementsNews
MediPharm Labs' Board Continues Value Destruction for Shareholders with Sale of Hope Facility
Complete Incompetence at the Board Level Results in Fire Sale of Treasured MediPharm Asset, the Hope Facility, to a Competitor
MediPharm Labs Closes $4.5 Million Sale of Hope, BC Facility and Announces Plans to Expand EU GMP Cultivation Capacity at Napanee Facility
TORONTO, June 05, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm"), a pharmaceutical company specialized in precision-based cannabinoids, announced the...
Leading Independent Proxy Advisor ISS Recommends that Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees; REJECTS Apollo's Arguments and Director Slate
TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoi...
MediPharm Labs Refuses to Answer Direct Questions Regarding Credible Securities Fraud Allegations Says Apollo Capital
Demands Management's Board Nominees John Medland and Emily Jameson Withdraw Immediately or Face Public Complicity in Ongoing Alleged Systemic Violations of Securities Laws
MediPharm Labs Responds to Fabricated Allegations from Dissident Shareholder
MediPharm Labs responds to allegations from dissident shareholder Apollo, intentionally or recklessly fabricated as part of its campaign of misinformation.
Alleged Securities Fraud at MediPharm Labs Says Apollo Capital
Multiple Highly Credible Sources Reveal Disturbing Evidence of Alleged Systemic Violations of Securities Laws at MediPharm Labs; Immediate Regulatory Action Demanded Apollo Capital's Six Director Nomi...
MediPharm Labs Board Issues Letter to Shareholders in Response to Inadequate Dissident Plan
TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today issued a Letter t...
MediPharm Labs Begins Production of First Order for International Expansion of Novel Cannabis Metered Dose Portfolio in the EU and United Kingdom Under Blackpoint Sales and Distribution Agreement
TORONTO, May 26, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision...
MediPharm Labs Cautions Shareholders about Dissident Nominees' Governance Failures at Check-Cap Ltd.
TORONTO, May 23, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (“MediPharm”, the “Company”, or “we”), a pharmaceutical company specialized in precision-based cannabinoids, today provided i...
Apollo Capital Comments on MediPharm Labs' Failure to Respond to Reasonable Offer to Ensure Fair, Lawful and Transparent 2025 Annual Meeting
MediPharm Labs Board Continues to Obstruct the Appointment and Oversight of an Independent Chair Failure to Appoint an Independent Chair to Oversee the Election of Directors at the Annual Meeting Prev...
MediPharm Achieves Key Milestone Toward $4.5 Million Cash Sale of Hope Facility, On Track to Close in June
TORONTO, May 22, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce ...
Apollo Capital Issues a With Prejudice Offer to MediPharm Labs and Its Board of Directors to Ensure Shareholder Rights Are Protected at the 2025 Annual Meeting
Believes the Board Continues to Take Oppressive Actions Which Fundamentally Disregard the Rights and Interests of Shareholders
MediPharm Labs Alerts Shareholders to Allegations Made Against Regan McGee in Multiple Litigation Filings
TORONTO, May 21, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today alerted its share...
COMPLETE Board Change is Urgently Needed at MediPharm Labs! Apollo Technology Capital Corporation Files Amended and Restated Proxy Circular Detailing Prolonged Underperformance, Strategic Failures, Excessive Executive Compensation, and Troubling Lack of Transparency Under Current Leadership
Launches Campaign Website at www.CureMediPharm.com , Which Articulates 5-Pillar Plan to Rebuild Company Details How MediPharm Labs is Hemorrhaging Money at an Alarming Rate and is on Pace to Run Out o...
Apollo Capital Warns MediPharm Shareholders of Continued Value Destruction and Insolvency Risk Following Disastrous Q1 Financial Results
MediPharm is Dangerously Low On Cash and is On Track to Run Out of Money by November Unless Wholesale Change Occurs MediPharm Lost Over $3.3 Million in Q1 2025 While Management Offered No Clear Plan t...
MediPharm Labs Raises Concerns About Poorly Qualified Dissident Nominees
TORONTO , May 15, 2025 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today provided its sharehol...
MediPharm Labs Corp. (MEDIF) Q1 2025 Earnings Call Transcript
MediPharm Labs Corp. (MEDIF Q1 2025 Earnings Conference Call May 14, 2025 10:00 AM ET Company Participants David Pidduck - President & Chief Executive Officer Greg Hunter - Chief Financial Officer Con...
Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders
Company Has Suspended Calls Since the Second Quarter of 2024 to Avoid Facing the Music for Board's and Management Team's Destruction of 99% of Stock's Value, Costing Shareholders $1 Billion Conferenc...
MediPharm Labs Announces Strong Q1 2025 Results
Achieves Positive Adjusted EBITDA(1) Revenue of $10.8 Million, an Increase of 11% over Q1 2024 87% Growth in International Medical Cannabis Revenue, Forming 55% of Total Revenue Gross Profit of $4.2 m...
MediPharm Labs Sets Date to Report First Quarter 2025 Financial Results
TORONTO , May 9, 2025 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based...
MediPharm Labs Responds to Dissident Shareholder's Filing
TORONTO , May 8, 2025 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is aware of the dissident pr...
Apollo Technology Capital Corporation to Nominate Six Highly Qualified Directors to MediPharm Labs' Board of Directors Following Years of Shareholder Value Destruction
Believes Board Change is Urgently Needed: Under the Current Board and Management, MediPharm Stock Price is Down More Than 99%, Costing Shareholders Nearly $1 Billion MediPharm's Board Cannot be Truste...
MediPharm Labs Reports Full Year & Fourth Quarter 2024 Results
Annual Net Revenue Increase of 27% to $42M, Driven by Record $18M International Medical Cannabis Revenue and Approaching Positive Adjusted EBITDA(1) for Q4. TORONTO , March 31, 2025 /PRNewswire/ - Med...
MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2024 Financial Results
TORONTO , March 26, 2025 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-ba...
MediPharm Labs Announces Termination of the Proposed Sale of Napanee Facility to Kensana Health
TORONTO , Feb. 10, 2025 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) ("MediPharm", "MediPharm Labs" or the "Company") has terminated the previously announced sale of its facility in ...